

Enclosure No:	4/AWMSG/0318
Agenda item No:	8 – AWMSG Five Year Strategy 2018–2023: <i>Supporting prudent prescribing to obtain the best outcomes from medicines for patients in Wales</i>
Author:	All Wales Therapeutics and Toxicology Centre
Contact:	Tel: 02920 71 6900 awttc@wales.nhs.uk

1.0 ACTION FOR AWMSG

AWMSG members are requested to consider the *AWMSG Five Year Strategy 2018–2023* for endorsement.

Members are also requested to volunteer as stakeholder leads and collaborate on delivering the recommendations.

2.0 PURPOSE

AWMSG is committed to ensuring that patients in Wales have access to clinically effective and cost-effective medicines that will improve their health outcomes. Over the next five years AWMSG will aim to ensure that prescribing in Wales is consistent with the optimal prescribing practices in the rest of the UK. The strategy for the next five years (1 April 2018–31 March 2023) builds on the success of the previous strategy (2013–2018).

3.0 BACKGROUND

The All Wales Medicines Strategy Group (AWMSG) is committed to supporting Welsh Government's Prudent Healthcare initiative, and the principles outlined in [Taking Wales Forward](#) and [Prosperity for All: the national strategy](#).

Prudent Healthcare – “*Healthcare that fits the needs and circumstances of patients and avoids wasteful care*” – will only be achieved by working in partnership with many organisations to deliver a medicines strategy in Wales that promotes safe and effective prescribing practices. The recommendations in this strategy are aligned to these principles to ensure healthcare fits the needs and circumstances of patients.

DRAFT FOR ENDORSEMENT

EXECUTIVE SUMMARY

- The All Wales Medicines Strategy Group (AWMSG) was established in 2002 to provide advice on new and existing medicines, medicines management and prescribing to the Welsh Government in an effective, efficient, timely and transparent manner.
- AWMSG brings together an expert panel of health professionals, scientists, health economists, industry representatives, patient advocates and lay representatives to reach a consensus on the use of new medicines and on policies that promote the best use of medicines, in order to achieve the best health outcomes for patients in Wales.
- There is broad geographical representation within AWMSG from across the whole of NHS Wales, supporting the aim of achieving equity of access to clinically effective and cost-effective medicines for patients in Wales. Two advisory subgroups report to AWMSG and provide expert advice: the New Medicines Group (NMG) and the All Wales Prescribing Advisory Group (AWPAG).

AWMSG and its subgroups are supported by the All Wales Therapeutics and Toxicology Centre (AWTTC) which co-ordinates AWMSG's work programme and prioritises objectives with Welsh Government.

- AWMSG is committed to supporting Welsh Government's national programme *Taking Wales Forward*¹. The Government's key themes as set out in *Prosperity for All: the national strategy* are: "*Prosperous and Secure, Healthy and Active, Ambitious and Learning, United and Connected*"².
- AWMSG will seek to ensure that Wales is globally responsible in areas such as medication safety. It will drive improvement in the economy by continuing to promote access to cost-effective medicines and prescribing across Wales. AWMSG is committed to responding to emerging challenges of new technology such as cell and gene therapy, and medicines optimisation in an ageing population. AWMSG is committed to working in partnership with the Welsh public, GP cluster groups and prescribers, and will explore new ways of working with these groups, including joined-up educational programmes which reinforce and build on what people and communities are currently doing.
- In 2014 the Minister for Health and Social Services presented a paper to Welsh Government on Prudent Healthcare. Prudent Healthcare is defined as "*Healthcare that fits the needs and circumstances of patients and avoids wasteful care*"³. This will only be achieved by working in partnership with many organisations to deliver a medicines strategy in Wales that promotes safe and effective prescribing practices.
- AWMSG seeks to support the application of the following Prudent Healthcare initiative principles in relation to the use of medicines³:
 - Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production;
 - Care for those with the greatest health need first, making the most effective use of all skills and resources;
 - Do only what is needed, no more, no less; and do no harm;
 - Reduce inappropriate variation using evidence-based practices consistently and transparently.

DRAFT FOR ENDORSEMENT

CONTENTS

EXECUTIVE SUMMARY.....2

INTRODUCTION..... 4

BACKGROUND 5

 Review of 2013–2018 strategy..... 5

 Principles underlying the 2018–2023 strategy..... 6

KEY RECOMMENDATIONS AND OUTCOMES 9

 1.0 Domain 1 – Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production..... 9

 2.0 Domain 2 – Care for those with the greatest health need first, making the most effective use of all skills and resources10

 3.0 Domain 3 – Do only what is needed, no more, no less; and do no harm11

 4.0 Domain 4 – Reduce inappropriate variation using evidence-based practices consistently and transparently.....13

REFERENCES.....16


APPENDIX 1. AWMSG STRATEGY TIMELINE17

DRAFT FOR ENDORSEMENT

INTRODUCTION

The All Wales Medicines Strategy Group (AWMSG) provides advice on newly licensed medicines and established medicines with new indications, and also develops guidance and conducts monitoring as part of its medicines optimisation programme. The medicines optimisation programme seeks to focus on patients and outcomes rather than processes and systems, and aims to support healthcare workers in advising patients on how they can achieve the best outcomes from their medicines.

AWMSG remains committed to providing authoritative advice to Welsh Government. It continues to develop mechanisms to assist with the implementation and audit of this advice within NHS Wales and regularly analyses prescribing data in order to benchmark performance and drive improvements in the service.



The work of AWMSG is planned by the AWMSG Steering Committee. This Committee prioritises AWMSG's work programme to ensure efficient use of resources.

Two advisory subgroups report to AWMSG and provide expert advice: the New Medicines Group (NMG) and the All Wales Prescribing Advisory Group (AWPAG). In addition, various working groups develop projects in specific areas, such as the National Prescribing Indicator Task and Finish Group. AWMSG and its subgroups are supported by the All Wales Therapeutics and Toxicology Centre (AWTTC) which co-ordinates AWMSG's work programme and prioritises objectives with Welsh Government. AWTTC consists of: the Patient Access to Medicines Service (PAMS); the Welsh Medicines Resource Centre (WeMeReC); the Yellow Card Centre Wales (YCC Wales); the Welsh Analytical Prescribing Support Unit (WAPSU); and the National Poisons Information Service (NPIS). AWTTC provides clinical, scientific and administrative support to AWMSG and its subgroups. Its roles include continuing development and support of the health technology appraisal (HTA) process, education in therapeutics and medicines safety, financial forecasting and horizon scanning.

DRAFT FOR ENDORSEMENT

BACKGROUND

AWMSG is committed to ensuring that patients in Wales have access to clinically effective and cost-effective medicines which improve patients' health outcomes. The strategy for the next five years (1 April 2018–31 March 2023), builds on the successes of the previous strategy, which was in place for the period 1 April 2013–31 March 2018⁴. AWMSG is aware of the future challenges of limited resources and new therapies (e.g. gene and cell therapies) and aims to adapt its strategy to the ever-changing NHS environment.

Review of 2013–2018 strategy

One of the key recommendations made within the 2013–2018 strategy was related to 'Partnership with the public' and ensuring patients and service users are involved in AWMSG's work and decisions as equal partners⁴. AWMSG has met both of the relevant outcomes for this recommendation through development of a Patient and Public Involvement Group (PAPIG) and a Citizens' Jury to report on antibiotic resistance. PAPIG meets on a regular basis, is an integral part of AWMSG processes and is consulted regularly on guideline development. The Citizens' Jury was led by Professor Marcus Longley and met over one week in the Cardiff City Hall in July 2016. After hearing all the evidence, the Jury made a series of recommendations which were submitted to Welsh Government.

Over the past five years, AWMSG has fulfilled its commitment to supporting the highest quality of prescribing for patients in Wales by developing and monitoring National Prescribing Indicators (NPIs), developing national guidelines and audits, and providing educational bulletins and prudent prescribing workshops.

NPIs are used to highlight therapeutic priorities for NHS Wales and compare the ways in which different prescribers and organisations use particular medicines or groups of medicines. Prescribing indicators should be evidence-based, clear, easily understood and allow health boards/trusts, practices and prescribers to compare current practice against an agreed standard of quality. Implementation of the NPIs has been successful in reducing much of the inappropriate variation in prescribing within Wales. AWMSG is committed to reducing inappropriate antibiotic use in order to reduce the risks of antibiotic resistance.

AWMSG also has an ongoing commitment to ensuring patient safety associated with the use of medicines. The reporting of spontaneous adverse drug reactions through the Yellow Card scheme (developed in 1964 in response to the thalidomide tragedy) is an important method of identifying new suspected adverse drug reactions and helps to prevent patients in Wales suffering medicines related harms. In the *AWMSG Five-year Strategy 2013–2018*, the recommendation was made to increase suspected adverse drug reaction reporting by healthcare professionals in Wales⁴. AWMSG, in association with the Yellow Card Centre Wales, introduced the Yellow Card NPI (or national reporting indicator). This, together with previous initiatives, resulted in Wales being the highest Yellow Card reporting region in the UK.

DRAFT FOR ENDORSEMENT

Between 1 April 2013 and 31 March 2017, AWMSG carried out 162 appraisals of which 147 (91%) medicines were approved for use within NHS Wales. To support the improved access to new medicines, during 2013–2018 AWMSG has:

- Enabled the appraisal of medicines identified as addressing a clear unmet need ahead of the publication of National Institute for Health and Care Excellence (NICE) advice.
- Strengthened clinical expert engagement in the appraisal process.
- Reviewed the process for appraising orphan and ultra-orphan medicines, and medicines developed specifically for rare diseases, and established the Clinician and Patient Involvement Group (CAPIG).
- Improved equity of access by enabling the appraisal in Wales of medicines that have received a negative recommendation from NICE but which are then funded in England via alternative national commissioning routes.
- Reviewed end-of-life processes.
- Redesigned its website.
- Developed a process to adopt NICE Highly Specialised Technology (HST) guidance (now superseded).
- Developed a Patient and Public Engagement Strategy.

Principles underlying the 2018–2023 strategy

Since the introduction of the 2013–2018 AWMSG Medicines Strategy the landscape of the NHS in Wales has changed significantly. We have a growing population – people are living longer, there are higher birth rates and lower infant mortality. There is no doubt that the service is under strain. However, there have been huge advances in relation to new and effective medicines. Those therapies, together with developments in information technology, provide a unique opportunity to introduce new approaches to innovation. These can produce efficiencies in the system and help NHS Wales face the ever-growing challenges. AWMSG is going to respond to these opportunities to ensure that patients in Wales can equitably access appropriate clinically effective and cost-effective new medicines at the appropriate time leading to improved patient health outcomes.

AWMSG has aligned the 2018–2023 medicines strategy with the Welsh Government programmes of Prudent Healthcare and Taking Wales Forward and also taken into consideration the Parliamentary Review of Health and Social Care in Wales report “*A Revolution from Within: Transforming Health and Care in Wales*”.

AWMSG is a Welsh Government advisory committee and relies on other organisations (both within and outside of NHS Wales) and AWTTTC to deliver the outcomes of the strategy. However, AWMSG will provide the strategic direction and framework to improve the health of people living in Wales.

The recommendations in this strategy are aligned to the four Prudent Healthcare initiative principles, to ensure healthcare fits the needs and circumstances of patients and actively avoids wasteful care that is not beneficial to patients. The four principles include:

- *Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production;*
- *Care for those with the greatest health need first, making the most effective use of all skills and resources;*
- *Do only what is needed, no more, no less; and do no harm;*
- *Reduce inappropriate variation using evidence-based practices consistently and transparently.*

DRAFT FOR ENDORSEMENT

Below is a summary of the key recommendations which align to the Parliamentary Review of Health and Social Care in Wales report *A Revolution from Within: Transforming Health and Care in Wales*

1. “Seamless care close to home” Recommendation 1, of Parliamentary Review of Health and Social Care in Wales report, *A revolution from Within: Transforming Health and Care in Wales*

- AWMSG will improve medication administration to vulnerable patients and will develop an All Wales Homecare prescribing and administration chart to ensure seamless care of medicines administration between the hospital and home.

2. “Improve population health and wellbeing through a focus on prevention”. Recommendation 2, Quadruple aim of Parliamentary Review of Health and Social Care in Wales report, *A Revolution from Within: Transforming Health and Care in Wales*

- AWMSG will reduce potential medication related harm by 50% over the next five years, in line with the WHO Global Patient Safety Strategy. This will ensure that Wales is “engaged and connected to the wider world” in line with “*Taking Wales Forward*” and fully engaged on the European and global stage.
- AWMSG will improve hospital recording of medication related admissions, carry out periodic audits and use the results to improve admissions over the five-year period.
- AWMSG will develop a nationally agreed multi-professional standard for medication reviews.
- AWMSG will work to prevent harm from medicines for patients in Wales by demonstrating an improvement of the rate of spontaneous yellow card reports of suspected adverse drug reactions by secondary care.
- AWMSG will develop safe medication systems for medicines.

3. “Increase the value achieved from funding of health and care through improvement, innovation, use of best practice and eliminating waste” Recommendation 2, Quadruple aim of Parliamentary Review of Health and Social Care in Wales report, *A Revolution from Within: Transforming Health and Care in Wales*

- AWMSG will review its process and policies to ensure it adapts to the changing landscape over the next five years to include appraisal of cell and gene therapies.
- AWMSG will maximise cost efficiencies by monitoring Wales Patient Access Schemes
- AWMSG will advise on disinvestment of medicines in order to make the most effective use of health care resources in Wales.
- By developing a collaborative approach and sharing best practice AWMSG will reduce inappropriate variation in achievement of National Prescribing Indicators (NPIs) between health boards.
- AWMSG will reduce medicines waste in Wales by 2023 by supporting current schemes and through the involvement of the public and patients.

4. “Putting the People in Control” Recommendation 4 of Parliamentary Review of Health and Social Care in Wales report, *A Revolution from Within: Transforming Health and Care in Wales*

- AWMSG will keep the public and patients at the heart of its work which aligns with Welsh Government’s Prudent Healthcare policy, *Prosperity for health*, and the Parliamentary review recommendation “Put the people in control”.
- AWMSG will involve patients in its work and will demonstrate an improvement in patient involvement over the next five years and understanding of the appraisal process in Wales.

DRAFT FOR ENDORSEMENT

5. “*Health & care system that is always learning*”. Recommendation 6, of Parliamentary Review of Health and Social Care in Wales report, *A Revolution from Within: Transforming Health and Care in Wales*

- AWTTTC will develop educational resources and demonstrate their relevance to stakeholders.

6. “*Harness Innovation and technology*” Recommendation 7, of Parliamentary Review of Health and Social Care in Wales report, *A Revolution from Within: Transforming Health and Care in Wales*

- AWMSG will improve healthcare outcomes in patients by the development of NPIs and by analysing prescribing data utilising BIG Data to demonstrate the evidence based benefit to patient safety, outcomes and care.
- AWMSG will support the introduction of e-prescribing in Wales over the next five years and, in line with the Welsh Government’s document *Inform Health and Care*, AWMSG will support the development of a single integrated electronic patient record.

A visual timeline displaying the outcomes AWMSG is seeking to achieve can be seen in Appendix 1.

DRAFT FOR ENDORSEMENT

KEY RECOMMENDATIONS AND OUTCOMES

1.0 Domain 1 – Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production

The Welsh Government’s document *Prosperity for All: the national strategy* states that “We want a Wales of connected communities, and that means making sure that all the links needed are in place to bring them together”².

AWMSG is committed to working in partnership with the public, patients and professionals, and recognises the importance of ensuring patients get the maximum benefit from their medicines.

Medicines waste has been highlighted as a priority by the Auditor General for Wales’ 2016 report, *Managing medicines in primary and secondary care*⁵, and AWMSG will work with all stakeholders to help develop a national plan to reduce medicines waste and improve adherence.

AWMSG is committed to providing fair and equitable prioritisation of healthcare and will work with patients and the public to improve communication of its decisions and ensure that clear reasons for its recommendations are made available.

Recommendations	Outcome	Target date
1.1 Partnership with the public		
AWMSG will ensure that patients and the public continue to be involved in its work as equal partners through the Patient and Public Interest Group (PAPIG).	Increased involvement of patients and the public in AWMSG work, and increased patient and public understanding of medicines access and medicines optimisation as measured by periodic surveys.	Annually until March 2023
Stakeholder lead: (volunteers/suggestions please) All Wales Therapeutics and Toxicology Centre		
1.2 Reduce medicines wastage		
AWMSG acknowledges that involvement of the public and patients is essential in addressing the problem of medicines waste in primary and secondary care. As part of its commitment to working in partnership with patients and the public, AWMSG will invite PAPIG and other public organisations to support the ongoing Medicines Waste campaign.	Reduction of medicines waste in Wales by 2023 as measured by cost of medicines returned.	Annually until March 2023
Stakeholder lead: (volunteers/suggestions please) Prof. Dyfrig Hughes/Dr Emily Holmes; CHEME, Bangor University		
1.3 Ensuring fair and equitable provision of healthcare		
AWMSG will ascertain the views of patients and the public (via PAPIG and other stakeholders) on the role of social value judgements in decision making related to medicines access, to ensure that co-production with patients and the public is an integral part of AWMSG’s HTA processes.	Stakeholders to develop an evidence based survey which will be conducted and completed, and findings presented to AWMSG for consideration/action.	March 2020
Stakeholder lead: (volunteers/suggestions please) Prof. Dyfrig Hughes; CHEME, Bangor University.		

DRAFT FOR ENDORSEMENT

2.0 Domain 2 – Care for those with the greatest health need first, making the most effective use of all skills and resources

The Welsh Government’s document *Prosperity for All: the national strategy* includes objectives to “*Build ambition and encourage learning for life*”, and “*Equip everyone with the right skills for a changing world*”². The Welsh Government document *Taking Wales Forward* also states that it will “*Invest in training NHS staff and create a single body to commission and provide training and education for all healthcare professionals, especially the primary care workforce to support the work of GPs*”¹.

AWMSG recognises the importance of workforce training in taking forward the Prudent Healthcare initiative and ensuring that patients receive the most appropriate treatment for their needs³. The contribution of all groups of healthcare professionals (e.g. doctors, pharmacists, nurses and professions allied to medicine) to medicines optimisation is vital, and AWMSG will work with Health Education and Improvement Wales (HEIW) and other key groups in Wales to promote education and training in this area⁶.

The Auditor General for Wales’ report identified that health bodies may not have a true picture of the cost of homecare services and advised a national audit of compliance with the Royal Pharmaceutical Society Wales’ *Handbook for Homecare Services in Wales*^{5,7}.

Recommendations	Outcomes	Target date
2.1 Workforce development		
AWMSG will encourage and support health boards/trusts to provide educational opportunities for healthcare professionals, including undergraduates, to become involved in local medicines optimisation issues. AWMSG, through AW TTC, will develop educational resources (including via digital platforms) to ensure that healthcare professionals have access to evidence-based information on current best practice in prudent prescribing, particularly to support the management of patients with multimorbidities requiring polypharmacy.	Continued improvement in satisfaction scores for educational initiatives and resources delivered by AW TTC.	Annually until 2023
Stakeholder lead: (volunteers/suggestions please)		
2.2 Medicines Homecare Services		
AWMSG will: work with key stakeholders to monitor Medicines Homecare Services in Wales; support health boards/trusts in the audit of compliance with measures set out in the <i>Handbook for Homecare Services in Wales</i> ⁷ ; and help develop an All Wales plan to ensure the most effective use of resources.	Audit compliance with, and review the impact of, the <i>Handbook for Homecare Services in Wales</i> ⁷ .	March 2020
Stakeholder lead: (volunteers/suggestions please)		
2.3 Safe Medication Systems		
To help protect patients, AWMSG will support the development of principles and policy across health and social care settings to ensure safe systems for medicines optimisation are available.	Review of policies for delivery of medication support in care homes and domiciliary settings.	March 2019
	Demonstration of improved medication administration to vulnerable patients through the implementation of agreed national principles and policy for delivery of medication support in care homes and domiciliary settings.	March 2021
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

3.0 Domain 3 – Do only what is needed, no more, no less; and do no harm

The Welsh Government’s document *Prosperity for All: the national strategy* has a key theme “*Healthy and Active*” noting that “*many of the conditions treated by the health service every day are avoidable*”, and that “*we need to prevent as many people as possible being held back by ill-health*”².

AWMSG recognises the importance of preventing avoidable medication-related hospital admissions in Wales, in line with observations within the Auditor General for Wales’ report that the current recording of medication-related admissions is poor⁵. Therefore, improving awareness of medication-related admission recording and supporting initiatives in order to improve patient outcomes is a priority within this AWMSG strategy.

Through the introduction of the Yellow Card NPI, AWMSG has helped to increase reporting of adverse drug reactions (ADRs) in primary care to 50% higher than the rest of the UK (Auditor General for Wales’ report). The Auditor General for Wales’ report, however, highlighted that only a third of secondary care doctors agreed/strongly agreed that the Yellow Card scheme is promoted effectively⁵. AWMSG will ask YCC Wales to identify initiatives to promote Yellow Card reporting by secondary care physicians and also by patients and carers.

AWMSG is committed to promoting medication safety by ensuring all health professionals in Wales have access to a standardised, nationally agreed, medication review process.

In line with the Welsh Government’s document *Taking Wales Forward* which states that Welsh Government “*will move more care and services from hospitals into communities, supported by integrated and sustainable Health and Care Services capable of meeting current demand and future need*”¹, AWMSG is committed to facilitating continuity of medicines care when moving patients between hospital and community by developing an all Wales single prescribing and administration medicines chart.

AWMSG will work with the All Wales Medical Genetics Service (AWMGS) as part of the Genomics for Precision Medicines Strategy in Wales with a particular focus on reducing ADR burden⁸.

The Welsh Government’s document *Taking Wales Forward* states that “*Wales is engaged and connected to the wider world*”¹ and in its document *Prosperity for All: the national strategy* states “*We will ensure Wales remains outward-looking and fully engaged on the European and global stage, fostering new relationships for trade and investment, and promoting the best of our nation world-wide*”². In line with the Welsh Government’s intention to engage in worldwide collaboration, AWMSG supports the goal of the World Health Organization (WHO) Global Patient Safety Challenge, *Medication Without Harm*: to reduce the level of severe, avoidable harm related to medications by 50% over 5 years, globally⁹.

Recommendations	Outcome	Target date/by
3.1 Medication-related admissions		
AWMSG will support the development of hospital recording of medication-related admissions (i.e. hospital admissions as a result of harm attributed to medication use) and support initiatives to reduce these admissions over the next five years.	Develop robust methodologies to conduct periodic audits of patient safety indicators, medication-related patient safety incidents and also monitoring of medication-related admissions using coding data.	Regularly until March 2023
	Application of the data to highlight priorities and measure improvement around medication related admissions.	Ongoing until March 2023
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

3.2 Medication review		
AWMSG is aware of the increasing prevalence of polypharmacy within the population of Wales ^{10,11} . AWMSG will work with stakeholders to help develop standardised medicine review tools for use by healthcare professionals.	Implement a nationally agreed, multi-professional standard for medicine reviews.	December 2020
Stakeholder lead: (volunteers/suggestions please)		
3.3 National prescribing and administration chart		
3.3.1 Until electronic prescribing is introduced across NHS Wales, AWMSG (through AWTTTC and the All Wales Quality and Patient Safety Group) will audit adherence to national prescribing standards and appropriate use of the single national in-patient prescribing chart.	Develop a baseline measure for compliance with the national prescribing standards, identify poor practice, and introduce interventions to address any shortcomings.	Annually
Stakeholder lead: (volunteers/suggestions please)		
3.3.2 AWMSG is committed to ensuring safe prescribing of medicines both in the hospital setting and at home. As more patients are cared for at home it is a priority to develop a single all Wales prescribing and administration chart for patients to use at home and in care settings. Building on the success of the Single National Inpatient Chart, AWMSG will support the development of an all Wales home care prescribing and administration chart	Development of an all Wales home care prescribing and administration chart	December 2019
Stakeholder lead: (volunteers/suggestions please)		
3.4 Medicine-related harm		
AWMSG is committed to reducing medicine-related harm over the next five years. AWMSG will identify areas of potential harm from prescribing medications in vulnerable groups of patients and, through development of learning resources and appropriate NPIs, will encourage safe prescribing in these areas.	Reduction in cases of potential medicine-related harm by 50% over the next 5 years in areas identified by NHS Wales, in line with the aims of the third WHO Global Patient Safety Challenge, <i>Medication Without Harm</i> ⁹ .	Ongoing until March 2023
Stakeholder lead: (volunteers/suggestions please)		
3.5 Pharmacovigilance		
Over the next five years, AWMSG will support the Yellow Card Centre Wales in promoting initiatives to improve healthcare professionals' understanding of the importance of ADRs and further improve reporting rates in secondary care and by patients and carers in Wales.	Roll-out of educational materials aimed at secondary care, primary care and the general public to improve understanding and rates of spontaneous reporting of suspected ADRs.	Ongoing until March 2023
Stakeholder lead: YCC advisory group		
3.6 Resource reallocation		
AWMSG is committed to making the most effective use of healthcare resources in Wales. Through an evidence-based approach, AWMSG will identify medicines which show limited efficacy and will advise on their future place in therapy in NHS Wales.	Development of a process to support evidence-based, appropriate disinvestment of medicines considered as low-priority in NHS Wales.	Ongoing until March 2023
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

4.0 Domain 4 – Reduce inappropriate variation using evidence-based practices consistently and transparently

The Welsh Government, in *Taking Wales Forward*, states “We need to go digital-first in our delivery of government services. We will lead by example, by challenging the health service and education sector to utilise every opportunity the digital age presents.”¹

Taking Wales Forward also states that “We need to support people when they need it most, and equip services to respond to challenges, such as an ageing population, a changing climate, new technologies and globalisation”¹.

AWMSG is committed to supporting Welsh Government’s aspiration for better use of new and improved technologies to deliver more effective, efficient and safe care.

The Auditor General for Wales’ report highlighted the national plan to implement electronic prescribing in Wales⁵. AWMSG is committed to continuing to engage with stakeholders to support the implementation of this important initiative in Wales.

AWMSG is dedicated to providing Chief Pharmacists, Medicines and Therapeutics Committees, and Medical Directors with information on medicines optimisation to ensure wide communication of prescribing issues across health boards/trusts.

AWMSG supports the need to have an effective repeat prescribing system within Wales, as identified in the Auditor General for Wales’ report⁵, in order to address the growing challenge of multi-morbidity and polypharmacy.

It has already been demonstrated that implementation of NPIs is associated with improvements in medicines usage in Wales. The Auditor General for Wales’ report highlighted that AWMSG should continue to develop NPIs to ensure the right patients are receiving the right medicines and establish whether those medicines are making a difference to people’s outcomes⁵.

AWMSG is committed to working with all stakeholders in order to continue providing authoritative, robust, transparent and timely HTAs, and also to providing prescribers in Wales with information on medicines usage in Wales. The New Treatment Fund (NTF) set up by Welsh Government aims to improve, and reduce inappropriate variation in, provision of clinically effective and cost-effective medicines for the people of Wales.

Recommendations	Outcomes	Achieved by
4.1 Transformational digital technology		
4.1.1 AWMSG will work with stakeholders, including the NHS Wales Informatics Service and NHS Wales Shared Services Partnership, to support the introduction of an electronic prescribing system to be used throughout NHS hospitals in Wales.	Support the introduction of an electronic prescribing system in Wales.	March 2023
4.1.2 AWMSG will promote wider access to GP records so that all pharmacists, community pharmacists and pharmacy technicians delivering clinical services on wards can access the system.	Support the introduction of pharmacy access to GP records.	March 2023
4.1.3 AWMSG will promote the development of a single integrated electronic patient record that can be accessed by all healthcare professionals to improve communication and improve the care pathways for patients in Wales (as proposed in “Inform Health and Care” ¹²).	Support the development of a single integrated electronic patient record.	March 2023
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

4.2 Nationally available medicines list		
AWMSG will support the development of a list of nationally available medicines (i.e. a list of medicines available in Wales, incorporating medicines that have received a positive appraisal from AWMSG and NICE) to support the introduction of electronic prescribing.	Development of a nationally available medicines list to support the introduction of e-prescribing in Wales.	December 2020
Stakeholder lead: (volunteers/suggestions please)		
4.3 Improving prescribing and medicines optimisation within NHS Wales		
AWMSG will task AW TTC with improving communication between health boards/trusts by holding annual update meetings to discuss AWMSG recommendations and best practice initiatives, to support a collaborative approach and reduce inappropriate variation in prescribing throughout NHS Wales.	Development of processes to measure inappropriate variation in NPI achievement rates between health boards.	March 2023
	Demonstrable reduction in inappropriate variation in achievement of NPIs between health boards.	March 2023
Stakeholder lead: (volunteers/suggestions please)		
4.4 Repeat prescribing systems		
AWMSG is committed to working with stakeholders to improve repeat prescribing systems. AWMSG will review and consider the recommendations of the Chief Pharmacist Task and Finish Group on repeat prescribing with regards to the planning and roll out of improved repeat prescribing systems.	Endorsement by AWMSG of the Chief Pharmacist Task and Finish Group recommendations on repeat prescribing.	December 2022
Stakeholder lead: (volunteers/suggestions please)		
4.5 National Prescribing Indicators		
AWMSG will work with health boards/trusts to develop NPIs that inform measurable improvements in the quality of healthcare and improved patient outcomes, and include audit and review activity. AWMSG is committed to using all available information technology to monitor the clinical appropriateness of the NPIs and achievement of desired outcomes.	Demonstrable improvement in healthcare outcomes for patients in Wales.	December 2022
Stakeholder lead: (volunteers/suggestions please)		
4.6 HTA – ensuring the appraisal process is reviewed and meets the developing needs of NHS Wales		
AWMSG will continue to provide an internationally respected HTA process for the introduction of new medicines for patients in Wales. AWMSG will be responsive to developments in the UK and EU HTA processes, to ensure it meets the changing needs of the NHS in Wales.	Report by AW TTC to be submitted to AWMSG to demonstrate improved collaboration with other UK HTA bodies and agencies involved in advice concerning the approval of therapeutic products (e.g. Rare Diseases Implementation Group, Health Technology Wales and Welsh Blood Service).	March 2023
	Survey—evidence of patient/public and healthcare professional confidence in AWMSG HTA processes.	At regular intervals until March 2023
	AW TTC reports will reflect that consideration has been given to all relevant factors when appraising orphan and ultra-orphan medicines and medicines developed specifically to treat rare diseases.	March 2023
	AWMSG, working with the Welsh Blood Service, will develop the appraisal process to include cell and gene therapy. AW TTC to provide a report to AWMSG on progress.	March 2019
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

4.7 Wales Patient Access Scheme – ensuring NHS Wales recoups any financial discounts		
AWMSG will facilitate patient access to medicines that would normally exceed expected levels of cost-effectiveness through continued development, application and monitoring of Wales Patient Access Schemes (WPAS) and systems to recoup the associated savings.	Maximised cost-efficiencies for early access to medicines whilst ensuring patient access to all medicines recommended via HTA by NICE or AWMSG.	March 2023
Stakeholder lead: (volunteers/suggestions please)		
4.8 Using data to improve patient outcomes		
AWMSG is committed to the regular analysis of prescribing data to ensure attention is focused on the areas of greatest benefit in terms of clinical effectiveness and cost-effectiveness of medicines for patients in Wales. AWMSG will engage with all stakeholders to utilise available databases and methods of analysis over the next five years.	Demonstrable evidence-based benefit to patient safety, outcomes and care associated with improved analysis of prescribing data.	March 2023
Stakeholder lead: (volunteers/suggestions please)		

DRAFT FOR ENDORSEMENT

REFERENCES

1. Welsh Government. Taking Wales Forward 2016-2021. 2016. Available at: <http://gov.wales/docs/strategies/160920-taking-wales-forward-en.pdf>. Accessed January 2018.
2. Welsh Government. Prosperity for All: the national strategy. 2017. Available at: <http://gov.wales/docs/strategies/170919-prosperity-for-all-en.pdf>. Accessed January 2018.
3. Welsh Government. Prudent healthcare – setting out the prudent principles. 2015. Available at: <http://www.prudenthealthcare.org.uk/principles/>. Accessed Nov 2017.
4. All Wales Medicines Strategy Group. AWMSG five-year strategy 2013–2018. Jan 2014. Available at: http://www.awmsg.org/docs/awmsg/awmsgdocs/AWMSG_Five-year_Strategy_2013-2018.pdf. Accessed Nov 2017.
5. Auditor General for Wales. Managing medicines in primary and secondary care. Dec 2016. Available at: <https://www.wao.gov.uk/system/files/publications/Medicines-management-2016-english.pdf>. Accessed Nov 2017.
6. Health Education and Improvement Wales. Position paper for boards of local health boards and trusts in Wales. Sep 2017. Available at: [http://www2.nphs.wales.nhs.uk:8080/PHWPapersDocs.nsf/\(\\$All\)/F74A9A56FAB0DE85802581A20050BD83/\\$File/17.280917%20-%20HEIW%20Governance%20Workstream%20170831%20HBs%20and%20Trusts%20Paper.pdf?OpenElement](http://www2.nphs.wales.nhs.uk:8080/PHWPapersDocs.nsf/($All)/F74A9A56FAB0DE85802581A20050BD83/$File/17.280917%20-%20HEIW%20Governance%20Workstream%20170831%20HBs%20and%20Trusts%20Paper.pdf?OpenElement). Accessed Nov 2017.
7. Royal Pharmaceutical Society Wales. Handbook for Homecare Services in Wales. Centre, AWTaT; Sep 2014. Available at: <http://www.awmsg.org/docs/awmsg/medman/Handbook%20for%20Homecare%20Services%20in%20Wales.pdf>. Accessed Nov 2017.
8. Welsh Government. Genomics for Precision Medicine Strategy. Jul 2017. Available at: <http://gov.wales/docs/dhss/publications/170802genomics-straten.pdf>. Accessed Nov 2017.
9. World Health Organization. Medication without harm – WHO Global Patient Safety Challenge. May 2017. Available at: <http://apps.who.int/iris/bitstream/10665/255263/1/WHO-HIS-SDS-2017.6-eng.pdf?ua=1&ua=1>. Accessed Nov 2017.
10. Statistics for Wales. Prescriptions by GPs in Wales, 2016–2017. Sep 2017. Available at: <http://gov.wales/docs/statistics/2017/170920-prescriptions-by-general-medical-practitioners-2016-17-en.pdf>. Accessed Nov 2017.
11. Statistics for Wales. Prescriptions dispensed in the community in Wales, 2016. May 2017. Available at: <http://gov.wales/docs/statistics/2017/170524-prescriptions-dispensed-community-2016-en.pdf>. Accessed Nov 2017.
12. Welsh Government. Informed Health and Care: A Digital Health and Social Care Strategy for Wales. 2015. Available at: <http://gov.wales/docs/dhss/publications/151215reporten.pdf>. Accessed January 2018.

DRAFT FOR ENDORSEMENT

APPENDIX 1. AWMSG STRATEGY TIMELINE



	YEAR 1	YEAR 2	YEAR 3	YEAR 4	YEAR 5	
Domain 1	1.1 Partnership with the public	Increase involvement and understanding <input checked="" type="checkbox"/>	Increase involvement and understanding <input checked="" type="checkbox"/>	Increase involvement and understanding <input checked="" type="checkbox"/>	Increase involvement and understanding <input checked="" type="checkbox"/>	Increase involvement and understanding <input checked="" type="checkbox"/>
	1.2 Reduce medicines wastage	Medicines wastage campaign	Medicines wastage campaign	Medicines wastage campaign	Medicines wastage campaign	Medicines wastage campaign
	1.3 Ensuring fair and equitable provision of healthcare	Conduct survey and present findings to AWMSG <input checked="" type="checkbox"/>				
Domain 2	2.1 Workforce development	Continue to provide educational materials <input checked="" type="checkbox"/>	Continue to provide educational materials <input checked="" type="checkbox"/>	Continue to provide educational materials <input checked="" type="checkbox"/>	Continue to provide educational materials <input checked="" type="checkbox"/>	Continue to provide educational materials <input checked="" type="checkbox"/>
	2.2 Medicines Homecare Services	Audit compliance with, and review the impact of, the Handbook for Homecare Services in Wales				
	2.3 Safe Medication Systems	Review policies	Demonstrate Improvement			
Domain 3	3.1 Medication-related admissions	Continue monitoring	Continue monitoring	Continue monitoring	Continue monitoring	Continue monitoring
		Application of data to highlight priorities and measure improvement				
	3.2 Medication review	Implement a nationally agreed multi-professional standard for medicine reviews				
	3.3 National prescribing and administration chart	Develop baseline for compliance	Audit and introduce interventions			
		Develop an all Wales homecare prescribing and administration chart				
	3.4 Medicine-related harm	Support reduction in cases of medicine-related harm				
3.5 Pharmacovigilance	Continue roll-out of educational materials to improve understanding and rates of spontaneous reporting of suspected ADRs					
3.6 Resource reallocation	Develop a process to support evidence-based, appropriate disinvestment of medicines considered as low priority in NHS Wales					

Survey
 Measure
 Audit
 Develop
 Endorse

DRAFT FOR ENDORSEMENT



Domain 4	4.1 Transformational digital technology	Support the introduction of an electronic prescribing system in Wales	
		Support the introduction of pharmacy access to GP records	
		Support the development of a single integrated electronic patient record	
	4.2 Nationally available medicines list	Develop nationally available medicines list to support introduction of e-prescribing in Wales	
	4.3 Improving prescribing and medicines optimisation within NHS Wales	Develop processes to measure inappropriate variation in NPI achievement rates between health boards	
		Demonstrate reduction in inappropriate variation in achievement of NPIs between health boards	
	4.4 Repeat prescribing systems	Endorsement by AWMMSG of the Chief Pharmacist Task and Finish Group recommendations on repeat prescribing	
	4.5 National Prescribing Indicators	Demonstrate improvement in healthcare outcomes for patients in Wales	
4.6 HTA—ensuring the appraisal process is reviewed and meets the developing needs of NHS Wales	Improve collaboration with other UK HTA bodies and agencies involved in advice concerning the approval of therapeutic products (e.g. Rare Diseases Implementation Group, Health Technology Wales and Welsh Blood Transfusion Service)		
	Improve patient/public and healthcare professional confidence in AWMMSG HTA processes	<input checked="" type="checkbox"/>	
	Improve patient/public and healthcare professional confidence in AWMMSG HTA processes	<input checked="" type="checkbox"/>	
	Demonstrate consideration of all relevant factors when appraising orphan and ultra-orphan medicines, and medicines developed specifically to treat rare diseases		
	With WBS, develop HTA process to include cell & gene therapy		
4.7 Wales Patient Access Scheme—ensuring NHS Wales recoups any financial discounts	Maximise cost-efficiencies for early access to medicines whilst ensuring patient access to all medicines recommended via HTA by NICE or AWMMSG		
4.8 Using data to improve patient outcomes	Demonstrate evidence-based benefit to patient safety, outcomes and care associated with improved analysis of prescribing data		

Survey
 Measure
 Audit
 Develop
 Endorse